← Back to all posts
Novo gets European approval to sell hemophilia drug
💊

Novo gets European approval to sell hemophilia drug

The European Commission has approved Novo Nordisk’s Frehemgo for marketing and sale in Europe. The medicine is intended for people with hemophilia A, an inherited condition that makes it harder for blood to clot and can make bleeding difficult to stop. The approval follows a recommendation from a committee of the European Medicines Agency in September. Novo is still awaiting approval to sell Frehemgo in the United States.
Read the original article ↗
Share